Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b Open-Label Rollover Study For Subjects Discontinuing From UK-453,061 Studies For Treatment Of HIV-1 Infected Subjects

Next Previous
Search
Trial Profile

A Phase 2b Open-Label Rollover Study For Subjects Discontinuing From UK-453,061 Studies For Treatment Of HIV-1 Infected Subjects

Status: Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 17 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lersivirine (Primary) ; Darunavir; Efavirenz; Emtricitabine/tenofovir disoproxil fumarate; Etravirine; Nucleoside reverse transcriptase inhibitors; Ritonavir
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Sponsors Pfizer

    • Most Recent Events

    • 31 Jul 2013 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 04 Apr 2011 Planned End Date changed from 1 Dec 2016 to 1 Aug 2017, as reported by ClinicalTrials.gov.
    • 01 Feb 2011 Additional location (Portugal) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top